What's driving the U.S. Direct-to-Consumer Genetic Testing Market trends? Key players Ancestry, Color Genomics, Easy DNA, Gene By Gene, Helix OpCo LLC, Identigene, Inc., Living DNA Ltd., Pathway genomics

The U.S. Direct-to-Consumer Genetic Testing Market report provides detailed competitive landscape of the U.S. market. It includes company, market share analysis, product portfolio of the major industry participants. The report provides detailed segmentation of the U.S. Direct-to-Consumer Genetic Testing industry based on product segment, technology and end user segment.

U.S. Direct-To-Consumer Genetic Testing Market is expected to exceed USD 850 million by 2025. Increasing public awareness pertaining to availability of DTC genetic testing kits will be a high impact rendering factor for the U.S. DTC genetic testing market growth.

Request a sample Report of U.S. Direct-to-Consumer Genetic Testing Market at: https://www.marketstudyreport.com/request-a-sample/2276199/?utm_source=OPR.com&utm_medium=SP

Growing demand for personalized DTC genetic testing services will be a high impact rendering factor for U.S. direct-to-consumer genetic testing market. DTC tests are user friendly and provide accurate results. Industry players focus on providing technologically advanced solutions that rises its adoption. For instance, 23andMe manufactures DTC test that utilizes genotype testing technology that provides data on health, carrier status, behavioral attributes for studying drug interactions. Therefore, growing availability of such advanced tests for detection of diseases will spur the industry growth. However, high cost of these kits may hamper the U.S. direct-to-consumer genetic testing market growth to some extent.

Some major findings of the U.S. direct-to-consumer genetic testing market report include:

o U.S. direct to consumer genetic testing industry is in developing stage and is yet to witness numerous growth opportunities with further advancements in technology.

o Benefits associated with DTC genetic tests such as pre-diseases diagnosis that prevents hazardous repercussions has boosted their demand.

o SNP chips is the fastest growing technology and is highly preferred since it provides accurate detection of defective genes in less time.

o The U.S. DTC genetic testing industry is currently dominated by few industry players. Major players operating in the U.S. direct-to-consumer genetic testing market are Ancestry, Color Genomics, 23andMe, FamilytreeDNA (Gene by Gene), Easy DNA, Full Genome, Pathway Genomics and Genesis Healthcare among others. These companies manufacture technologically advanced genetic tests that renders them with competitive advantage.

Rising incidence of genetic diseases will accelerate demand for direct-to-consumer genetic testing kits over the forecast period. Genetic disorders such as achondroplasia, Parkinson?s and Alzheimer?s diseases are amongst the major ailments that cause adverse effect on an individual?s life. Direct access to genetic tests allows patients to know the probability of acquiring such disorders that has reduced the mortality rates. As a result, DTC genetic testing kits have crucial role in recognizing the genetic alterations, thereby escalating its demand in coming years.

Predictive testing segment is anticipated to witness over 16% CAGR throughout the analysis timeframe. Increasing prevalence of genetic diseases will prove beneficial for the U.S. direct-to-genetic testing market growth. Predictive testing helps in detecting the disease before the onset of the disease that in turn will help in reducing the morbidity and mortality rate. Aforementioned factors will escalate the segment growth in near future.

Single nucleotide polymorphism (SNP) chips segment valued for more than USD 140 million in 2018 and it will grow substantially over the forecast period. SNP chips helps in analyzing gene sequences at a particular resolution that reveals detailed analysis regarding defective genes. SNP chips specifically detect changes at molecular level that further increases the efficiency of tests. Therefore, SNP technology is highly preferred during drug discovery process that should augment the segment growth.

Companies are investing in operational activities to offer reliable DTC tests to end-users. Moreover, they are also adopting numerous strategic initiatives such as acquisitions, mergers, product launches, geographical expansions and collaborations to acquire significant market share, sustain the competition and gain competitive advantage over others. For instance, in July 2018, 23andme announced collaboration with GlaxoSmithKline (GSK) company. Collaboration will enable the company to discover therapeutics to treat genetic diseases that enables company to expand its share in the DTC genetic testing market.

Table of Contents:

Chapter 1. Methodology

1.1. Methodology

1.2. Market definition

1.3. Forecast parameters

1.4. Data sources

1.4.1. Secondary

1.4.1.1. Paid sources

1.4.1.2. Unpaid sources

1.4.2. Primary

Chapter 2. Executive Summary

2.1. U.S. Direct-To-Consumer (DTC) genetic Testing industry 360 degree synopsis, 2014 - 2025

Chapter 3. U.S. Direct-To-Consumer (DTC) Genetic Testing Industry Insights

Chapter 4. U.S. Direct-To-Consumer (DTC) Genetic Testing Market, By Test Type

Chapter 5. U.S. Direct-To-Consumer (DTC) Genetic Testing Market, By Technology

Chapter 6. U.S. Direct-To-Consumer (DTC) Genetic Testing Market, By Country

Chapter 7. U.S. Direct-To-Consumer (DTC) Genetic Testing Market Company Profiles

Ask for Discount on U.S. Direct-to-Consumer Genetic Testing Market Report at: https://www.marketstudyreport.com/check-for-discount/2276199/?utm_source=OPR.com&utm_medium=SP

Related Reports: https://www.openpr.com/news/1998919/what-s-driving-the-biological-safety-testing-market-size-key

Contact Us:
Market Study Report LLC.
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: www.marketstudyreport.com
Blog: www.marketstudyreport.com/

About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

This release was published on openPR.